Daina Graybosch

Stock Analyst at Leerink Partners

(0)
# 4626
Out of 5,319 analysts
132
Total ratings
25.00%
Success rate
-21.57%
Average return
21 Stocks
Name Action Price Target Current % Upside Ratings Updated
TSVT 2seventy bio
Downgrades: Market Perform
9 5
4.99 0.2% 6 Mar 11, 2025
MRK Merck & Co
Maintains: Outperform
136 119
77.92 52.72% 19 Jan 13, 2025
LVTX LAVA Therapeutics
Downgrades: Market Perform
11 2
1.34 49.25% 6 Dec 12, 2024
BOLT Bolt Biotherapeutics
Downgrades: Market Perform
3 1
0.35 185.71% 8 May 15, 2024
ACLX Arcellx
Maintains: Outperform
35 39
62.01 -37.11% 5 Mar 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
5 3
0.64 368.75% 10 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
20 14
0.54 2492.59% 4 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
62 10
1.11 800.9% 7 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
100 60
0.73 8119.18% 7 Dec 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
10 9
1.94 363.92% 10 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 38
7.88 382.23% 2 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
30 8
3.97 101.51% 4 Aug 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
223 224
98.88 126.54% 16 Jul 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
30
1.8 1566.67% 1 Jul 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
21 7
n/a n/a 4 Jun 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
60 59
6.46 813.31% 7 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
18 17
0.91 1768.13% 3 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
25 2
n/a n/a 6 Apr 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
16 9
1.49 504.03% 4 Feb 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
5 6
n/a n/a 2 Apr 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
68
n/a n/a 1 Dec 11, 2019